Atorvastatin calcium dispersible tablets

Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, which reduces plasma cholesterol and lipoprotein levels by inhibiting the synthesis of HMG-CoA reductase and cholesterol in the liver, and enhances the uptake and metabolism of LDL by increasing liver LDL receptors on cell surfaces. Atorvastatin reduces LDL cholesterol production and the number of LDL cholesterol particles. Atorvastatin causes a significant and persistent increase in LDL cholesterol receptor activity, resulting in beneficial changes in circulating LDL cholesterol particles. Atorvastatin can effectively reduce LDL levels in patients with homozygous familial hypercholesterolemia, for whom lipid-lowering drugs are generally ineffective.

This product is white or off-white tablets.

Hypercholesterolemia; patients with coronary heart disease or coronary heart disease-related critical illnesses (such as diabetes, symptomatic atherosclerotic disease, etc.) combined with hypercholesterolemia or mixed dyslipidemia.

Before starting treatment with this product, patients should follow a standard low-cholesterol diet and maintain a reasonable diet throughout the treatment period. The dose should be adjusted individually based on the baseline level of low-density lipoprotein cholesterol, treatment goals, and the patient's treatment effect. The commonly used starting dose is 10 mg once a day. The dose adjustment interval should be 4 weeks or longer. The maximum dose of this product is 80 mg once a day. The daily dose of atorvastatin can be taken once at any time of the day and is not affected by meals. For patients at low risk of cardiovascular events, the treatment goal is LDL-C <4.14mmol/L (or <160mg/dL) and total cholesterol <6.22mmol/L (or <240mg/dL). The treatment goal for moderate-risk patients is LDL

1. The most common adverse reaction of this product is gastrointestinal discomfort, and others include headache, rash, dizziness, blurred vision and taste disturbance. 2. It may occasionally cause a reversible increase in blood aminotransferase. Therefore, liver function needs to be monitored. 3. Rare adverse reactions include impotence and insomnia. 4. Rare adverse reactions include myositis, myalgia, and rhabdomyolysis, which are manifested as muscle pain, fatigue, fever, and are accompanied by increased blood creatine phosphokinase, myoglobinuria, etc. Rhabdomyolysis can lead to renal failure, but it is rare. 5. The combination of this product with immunosuppressants, folic acid derivatives, niacin, gemfibrozil, erythromycin, etc. may increase the risk of myopathy. 6. There have been reports of hepatitis, pancreatitis and allergic reactions such as angioedema.

People who are allergic to this product are prohibited from using it, and those with allergic constitutions should use it with caution.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

1. The combination of this product with oral anticoagulants can prolong the prothrombin time and increase the risk of bleeding. 2. The combination of this product with immunosuppressants such as cyclosporine, erythromycin, gemfibrozil, niacin, etc. can increase the risk of myolysis and acute renal failure. 3. Colestipol and cholestyramine can reduce the bioavailability of this product, so this product should be taken 5 hours after taking the former.

Keep away from light and store below 28℃

10mg

24 months

Guangdong Baike Pharmaceutical Co., Ltd.

• Founded in:

  2010-09-19

• Address:

  Yangjiang City Jiangcheng District Chengxi Mayan

• Tax NO.:

  9144170256255788XK

• Registered Funds:

  20 million yuan

• Website:

  Log in to view

• Email:

  Log in to view